Phase II Study to Evaluate Telisotuzumab Adizutecan in Combination With RC148 as First-Line Treatment for Patients With Non-Squamous Non-Small-Cell Lung Cancer

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
To Evaluate the Safety, Tolerability, and Preliminary Antitumor Efficacy of RC148 in Combination with Telisotuzumab adizutecan as First-line Treatment for Locally Advanced or Metastatic Non-Squamous Non-Small-Cell Lung Cancer
Epistemonikos ID: ef2ddd38a452cf76fa38f1338a7054e6704a00e3
First added on: Oct 15, 2026